Transmucosal delivery system for medical marijuana
PUGE is working to finalize its design patent for a new transmucosal (nasal spray) delivery system for medical marijuana.
Skin patches for the delivery of
PUGE is conducting feasibility studies on
transdermal (skin) patches for the delivery of
Infused beverages for the delivery of medical marijuana.
PUGE is researching naturally occurring terpenes, similar to essential oils, found in the cannabis plant that can be manipulated to create various flavor profiles.
Medicinal Marijuana Applications:
Cancer, Diabetes, HIV/AIDS, Pain Relief, Multiple Sclerosis, Alzheimer's Disease, Asthma, Glaucoma, Brain Cancer, ALS symptoms, Crohn's disease, Insomnia
“The best way to estimate the potential size of the legal market for cannabis begins with the illegal market – which is somewhere north of $18 billion a year in pot Americans consume already”
- Harvard Economist, Jeffrey Miron.
What’s the Opportunity?
Currently, there are far more applications for medical marijuana than there are methods for meeting those needs.
Today, the primary delivery system for medical marijuana is smoking it, which can be harmful to the lungs and contain other adverse side effects.
However, various other delivery systems that are already being used for common household drugs may also be useful for the delivery of medicinal marijuana.
For example, inhalers, transdermal patches, eye drops, tongue strips, tonics and other edible substances are all being used to deliver medicine to millions of people.
In fact, in 2012, the global drug delivery market was worth $142.5 billion! Cannabis Biotech is endeavoring to connect explosive new medical marijuana products with the highly profitable industry of drug delivery systems.
How can I make Money in PUGE?
Cannabis Biotech is focusing on technologies whereby medical marijuana can be effectively administered through the delivery systems such as nasal sprays, skin patches and infused beverages.
Our emerging technologies have the potential to replace competing products in the marketplace which are much less standardized and regulated.
- Ron Leyland, President and CEO
At PUGE, our team of researchers and scientists is working hard to develop delivery systems that can effectively deliver a reliable, standard dose of medicine containing the preferred chemical compounds contained in marijuana without the side effects from smoking it. We are working to serve a rapidly expanding patient base that already contains more than 2.4 million registered medical marijuana users nationwide.
President Barack Obama and federal officials have previously said marijuana users would not be targets for prosecution. But this September was the first time federal officials have offered state-legal marijuana businesses that follow strict rules explicit cover from prosecution.
PUGE is currently working to finalize its design patent for a new transmucosal (nasal spray) delivery system for medical marijuana. The sinuses have been a natural conduit to the body since the beginning of time. Practitioners now recognize the rapid onset, relative reliability, and general lack of patient discomfort when drugs are administered by the transmucosal route. By linking the benefits of medical marijuana to this powerful delivery system, PUGE is working to position itself as an industry leader in medical marijuana pharmaceuticals.
Nasal spray delivery systems have already been proven by the major pharmaceutical companies. Flonase (fluticasone propionate) manufactured by GlaxoSmithKline (NYSE: GSK, Rhinocort Aqua (budesonide) by AstraZeneca (NYSE: AZN), and Ortivine Adult Metered Dose by Novartis (NYSE: NVS) are all blockbuster medications that generate hundreds of millions in sales.
PUGE is conducting feasibility studies on transdermal (skin) patches for the delivery medical marijuana.
Transdermal patches contain multi-layered gels or reservoirs infused with active ingredients. Small amounts of these active ingredients are slowly absorbed through the skin and enter the blood, administering consistent and reliable doses to the consumer. The long-acting, time-released patch is an ideal delivery system for relief of chronic symptoms.
In 1992, NicoDerm CQ, famously coined “the patch,” was released to assist those wishing to receive nicotine without the harmful effects of smoking it. NicoDerm sold over $186 million dollars in patches in the first year!
Now, 20 years later, loosening state and federal regulation is creating an electric environment where medical marijuana patches are on the horizon and coming soon.
PUGE is also conducting feasibility tests on infused beverages for the delivery of medical marijuana compounds. The infused beverages market has exploded in the last two decades. In 2012 Red Bull’s sales reached $2.9 billion worldwide!
Consumers have embraced the idea of using beverage products to get their fix. However, some argue that energy drinks don’t have the same great flavors as their favorite colas. PUGE may have an answer for this.
PUGE is researching naturally occurring terpenes, similar to essential oils, found in the cannabis plant that can be manipulated to create various flavor profiles. With over 200 terpenes found in cannabis, these naturally occurring compounds allow for ample flavor combinations.